222 related articles for article (PubMed ID: 22468893)
1. Psoriasis drug discovery: methods for evaluation of potential drug candidates.
Svensson L; Røpke MA; Norsgaard H
Expert Opin Drug Discov; 2012 Jan; 7(1):49-61. PubMed ID: 22468893
[TBL] [Abstract][Full Text] [Related]
2. Murine models of psoriasis and their usefulness for drug discovery.
Chuang SY; Lin CH; Sung CT; Fang JY
Expert Opin Drug Discov; 2018 Jun; 13(6):551-562. PubMed ID: 29663834
[TBL] [Abstract][Full Text] [Related]
3. A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.
Campa M; Menter A
Expert Opin Investig Drugs; 2016 Nov; 25(11):1337-1344. PubMed ID: 27687859
[TBL] [Abstract][Full Text] [Related]
4. New therapies under development for psoriasis treatment.
García-Pérez ME; Stevanovic T; Poubelle PE
Curr Opin Pediatr; 2013 Aug; 25(4):480-7. PubMed ID: 23838833
[TBL] [Abstract][Full Text] [Related]
5. Emerging oral drugs for psoriasis.
Mahmood T; Zaghi D; Menter A
Expert Opin Emerg Drugs; 2015 Jun; 20(2):209-20. PubMed ID: 25643592
[TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery.
Petersen TK
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):104-15. PubMed ID: 16918710
[TBL] [Abstract][Full Text] [Related]
7. Translational dermatology in drug discovery: perspectives for integrating humanized xenograft models and experimental clinical studies.
Petersen TK; Sørensen P
Drug Discov Today; 2008 Mar; 13(5-6):240-6. PubMed ID: 18342800
[TBL] [Abstract][Full Text] [Related]
8. Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).
Chiricozzi A; Saraceno R; Novelli L; Fida M; Caso F; Scarpa R; Costa L; Perricone R; Romanelli M; Chimenti S; Chimenti MS
Expert Opin Ther Pat; 2016 Jul; 26(7):757-66. PubMed ID: 27266423
[TBL] [Abstract][Full Text] [Related]
9. Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100.
Manalo IF; Gilbert KE; Wu JJ
J Drugs Dermatol; 2015 Oct; 14(10):1086-8. PubMed ID: 26461817
[No Abstract] [Full Text] [Related]
10. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
11. Pimecrolimus for psoriasis.
Ayer J; Young HS
Expert Opin Pharmacother; 2013 Apr; 14(6):767-74. PubMed ID: 23461536
[TBL] [Abstract][Full Text] [Related]
12. Current and Under Development Treatment Modalities of Psoriasis: A Review.
Albaghdadi A
Endocr Metab Immune Disord Drug Targets; 2017; 17(3):189-199. PubMed ID: 28782467
[TBL] [Abstract][Full Text] [Related]
13. Integrative clinical transcriptomics analyses for new therapeutic intervention strategies: a psoriasis case study.
Qu XA; Freudenberg JM; Sanseau P; Rajpal DK
Drug Discov Today; 2014 Sep; 19(9):1364-71. PubMed ID: 24662034
[TBL] [Abstract][Full Text] [Related]
14. [The biological treatments for moderate to severe plaque psoriasis].
Thielen AM; Marazza G
Rev Med Suisse; 2008 Apr; 4(155):1089-90, 1092-4. PubMed ID: 18610721
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo culture of lesional psoriasis skin for pharmacological testing.
Tiirikainen ML; Woetmann A; Norsgaard H; Santamaria-Babí LF; Lovato P
J Dermatol Sci; 2020 Feb; 97(2):109-116. PubMed ID: 31948839
[TBL] [Abstract][Full Text] [Related]
16. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab.
Reich K; Griffiths CE
Arch Dermatol Res; 2008 Nov; 300(10):537-44. PubMed ID: 18784934
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine in the treatment of psoriasis.
Gulliver WP
Cutis; 2000 Nov; 66(5):365-9. PubMed ID: 11107522
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in randomized controlled trials in psoriasis: what has changed over the last 20 years?
Morsy H; Kamp S; Jemec GB
J Dermatolog Treat; 2007; 18(5):261-7. PubMed ID: 17917937
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
20. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
